# Korean Post-marketing Surveillance for Onglyza®

> **NCT01575483** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3433 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** No Intervention (subjects were previously treated with Onglyza®)

## Key facts

- **NCT ID:** NCT01575483
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-01
- **Primary completion:** 2016-09-07
- **Final completion:** 2016-09-07
- **Target enrollment:** 3433 (ACTUAL)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01575483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01575483, "Korean Post-marketing Surveillance for Onglyza®". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01575483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*